Schrodinger Q3 rev $37M (+24% YoY); Lilly collab up to $425M; FY22 guide narrowed

Schrodinger, Inc.

2022-Q3 EPS reported -$1.71 revenue$124,112,000

Q3 total revenue $37.0M (+24% YoY); drug discovery $12.3M (+121%); software $24.7M (+2%)
Net loss $39.9M vs $35.0M; cash $479M vs $513M at June 30, 2022
Entered collaboration with Lilly; up to $425M in milestones plus tiered royalties
Phase 1 trial of MALT1 inhibitor SGR-1505 open for patient enrollment
FY22 total revenue guide narrowed to $167-175M; software rev lowered to $122-127M; drug discovery raised to $45-48M

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Schrodinger, Inc. updated its the fiscal year ending December 31, 2022 guidance (reaffirmed).

Period: the fiscal year ending December 31, 2022
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Total revenue is now expected to range from $167 million to $175 million, compared to the prior expectation of $161 million to $181 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Schrodinger, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022, Schrödinger, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Schrodinger, Inc. filing history →

Source: SEC EDGAR

accession 0001490978-22-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.